Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines

Anna Dalla Pietà, Debora Carpanese, Antonella Grigoletto, Anna Tosi, Silvia Dalla Santa, Gabriel Kristian Pedersen, Dennis Christensen, Laura Meléndez-Alafort, Vito Barbieri, Paola De Benedictis, Gianfranco Pasut, Isabella Monia Montagner and Antonio Rosato

One of the main goals of vaccine research is the development of adjuvants that can enhance immune responses and are both safe and biocompatible. We explored the application of the natural polymer hyaluronan (HA) as a promising immunological adjuvant for protein-based vaccines. Chemical conjugation of HA to antigens strongly increased their immunogenicity, reduced booster requirements, and allowed antigen dose sparing. HA-based bioconjugates stimulated robust and long-lasting humoral responses without the addition of other immunostimulatory compounds and proved highly efficient when compared to other adjuvants. Due to its intrinsic biocompatibility, HA allowed the exploitation of different injection routes and did not induce inflammation at the inoculation site. This polymer promoted rapid translocation of the antigen to draining lymph nodes, thus facilitating encounters with antigen-presenting cells. Overall, HA can be regarded as an effective and biocompatible adjuvant to be exploited for the design of a wide variety of vaccines.

Keywords: Hyaluronan; natural polymer; immunological adjuvant; HA-bioconjugate vaccines

Cellular & Molecular Immunology (2021) 18:1197–1210; https://doi.org/10.1038/s41423-021-00667-y

INTRODUCTION

Hyaluronan (HA) is an anionic, linear, nonsulfated glycosaminoglycan that is composed of repeating units of D-glucuronic acid and N-acetyl-D-glucosamine linked through alternating β-1,3 and β-1,4 glycosidic bonds. HA is ubiquitously present in the human body as the primary component of the extracellular matrix. In addition, its remarkable inherent physicochemical properties, such as mucoadhesiveness, biodegradability, biocompatibility, and lack of toxicity, make this natural polymer appealing for several medical applications. Among these applications, HA has been successfully exploited as a carrier for proteins, peptides, cytokines, nucleotide therapeutics, and anticancer drugs, ensuring their targeted and long-acting delivery and water solubility. HA is present in tissues in a wide range of molecular weights (MWs), each endowed with different biological functions. Indeed, while native high MW (> 10^3 kDa) HA promotes tissue integrity and has immunosuppressive functions, low MW (LMW, < 10^3 kDa) fragments produced during various physiological and pathological processes are characterized by immunostimulatory, proinflammatory, and strong angiogenic properties. The biological behavior and turnover of HA are based on interactions with specific receptors, some of which mediate polymer endocytosis (HA receptor for endocytosis); others, its cellular uptake and degradation (CD44), signal transduction (receptor for hyaluronate-mediated motility), and regulation of homeostasis and catabolism (lymphatic vessel endothelial hyaluronan receptor-1, LYVE-1). Of note, HA also plays critical roles in both innate and adaptive immune responses by direct interactions not only with the abovementioned receptors, but also with Toll-like receptors (TLRs). In the latter interactions, HA fragments act as endogenous damage-associated molecular pattern molecules (DAMPs), which are recognized by TLR2 and TLR4 receptors expressed by a wide range of immune cells, including dendritic cells (DCs), monocytes, natural killer cells, and neutrophils. In addition, TLR2 functions as a costimulatory molecule in all activated T cells, including memory T-cell subsets.

Although some authors have described HA as a TLR agonist able to induce sterile inflammation by activating DCs and stimulating the production of cytokines, the potential of HA as an effective immunostimulatory and immunomodulatory agent for medical applications has been poorly investigated. Notably, TLR agonists are emerging as a new outstanding class of vaccine adjuvants since they offer a unique possibility of orchestrating adaptive immune responses by finely regulating the crosstalk between innate and adaptive immunity. In particular, this kind of vaccine adjuvant has been reported to induce the activation and maturation of DCs, increase cross presentation and cross priming, and stimulate memory responses. Additionally, different TLR ligands can be exploited to engage different receptors and hence to finely tune the type of Th immune responses elicited against a...
specific antigen. Therefore, TLR agonists constitute an appealing group of agents to overcome the limitations of commercially available adjuvants, first and foremost, the inability to induce effective Th1 immune responses, as in the case of alum, which is the most commonly used adjuvant worldwide. Notably, AS04 and AS01 \(^{19,20}\) are two TLR4 agonist-based adjuvants that have entered the European market, thus underlying the possibility that ligands of this TLR may constitute a highly promising class of vaccine adjuvants overall. However, even though these formulations have demonstrated good safety and effectiveness profiles, there is still much to do to further increase their effectiveness for a broader spectrum of antigens and applications. To this end, one strategy might be direct conjugation of antigens to TLR agonists, as suggested by several authors. Indeed, conjugation permits codelivery of TLR agonists and antigens to APCs, resulting in increased antigen presentation and processing efficiency.\(^{22,23}\) However, conjugation of TLR agonists to antigens entails careful selection of compounds, chemical coupling strategies, and conjugation sites.\(^{24}\)

Here, we describe results indicating that LMW HA fragments of a determined size (~200 kDa) are well suited for the development of a wide range of protein-based vaccines, where the polymer moiety is endowed not only with carrier properties but also remarkable immunostimulatory capacity. This application of HA as an immunological adjuvant strictly depends on covalent conjugation of protein antigens. All HA-based bioconjugates are characterized by impressive activities as immune activators and modulators and finely tuned antigen-specific adaptive immune responses, suggesting that HA can be exploited as a natural, biocompatible, and versatile adjuvant for protein-based vaccination strategies.

**MATERIALS AND METHODS**

Synthesis of HA-antigen conjugates

Synthesis of HA-acetal was carried out as reported elsewhere.\(^{3}\) Briefly, HA of the selected MW (Contipro or Neore Pharmaceutical Group Co.) was dissolved in DMSO, and the carboxylic groups were activated with 1,\(^{1}\)polyoxyethylene diethyl acetal (Sigma-Aldrich). After 30 min, 4-aminobutyraldehyde diethyl acetal (Sigma-Aldrich) was added, and the mixture was allowed to react for 12 h. The HA-acetal product was recovered through ethanol precipitation and washed with \(\text{EtOH} \cdot \text{H}_2\text{O}\) solutions. Then, the washed polymer was dissolved in water and extensively dialyzed against sterile water prior to lyophilization. The derivatization degree was determined by proton nuclear magnetic resonance (\(1\text{H-NMR}\)).\(^{25}\) Different antigens, i.e., ovalbumin (OVA, Hyglos GmbH); human superoxide dismutase (SOD), bovine serum albumin (BSA), human growth hormone (hGH, Sigma-Aldrich); tetanus toxoid (TT, Alomone Labs); recombinant influenza A virus (H5N1, Sino Biological Inc.; a recombinant immunoglobulin (Ig) light chain variable region (\(\text{K} \text{l} \text{s} \text{C} \text{K} \text{D} \text{R}\)) a gift kind from Prof. R. Dolcetti, Centro di Riferimento Oncologico di Aviano (CRO-IRCCS), Aviano, Italy); and rabies virus G glycoprotein (RABV G; obtained from Challenge Virus Strain—\(\text{ATCC VR-995}\)) propagated in BHK-21 cells (\(\text{ATCC CCL-10}\)), and purified as previously described,\(^{26}\) were conjugated to HA-acetal using a general procedure for each antigen. As an example, the reaction for the preparation of HA200kDa-OVA is described below. HA200kDa-acetal (5 mg, 0.38 \(\mu\)mol; degree of acetal modification 3% mol/mol) was dissolved in 25 mM \(\text{NaH}_2\text{PO}_4\) pH 2.1 and incubated for 1 h at 60 °C. After cooling to room temperature (RT), the pH value of the solution was raised to the target pH (8.0) with NaOH. After 1 h, \(\text{NaBH}_3\text{CN}\) was added, and the reaction was stirred at RT for 48 h. Then, three equivalents of glycine with respect to each equivalent of aldehyde in the starting HA were used to quench all the residual aldehyde groups. The conjugate was purified from unreacted OVA by gel filtration chromatography using Sephadex \(\times\) G-75 resin (dry bead diameter 40–120 \(\mu\)m) and eluted with 0.1 M \(\text{Na}_3\text{HPO}_4\) and 0.2 M NaCl (pH 7.2). The fractions were collected and concentrated with Amicon Ultra Centrifugal filters (Millipore, Merck), and the purity was confirmed by size exclusion chromatography (SEC-HPLC). The product was extensively dialyzed against sterile water and lyophilized with five equivalents of trehalose with respect to protein. The total protein content was determined by averaging the results obtained by a bicinchoninic acid colorimetric assay and measurement of the absorbance at 280 nm. The size of HA and HA-OVA conjugates was measured by dynamic light scattering (DLS, Zetasizer Nano ZS, Malvern, UK). The absence of LPS contamination after the conjugation process was evaluated using a commercial kit (PYROGENT™ Gel Clot LAL Single Test Vial) with a sensitivity of 0.06 EU/mL (Lonza). To investigate the in vivo biodistribution, OVA and HA-OVA conjugates were labeled with either Cy5.5 or AF647 (GE Healthcare Bio-Sciences AB and Thermo Scientific, respectively) according to the manufacturer’s instructions. The dye-labeled compounds were purified from the unreacted dye through Pierce™ Dye Removal Columns.

Preparation of other adjuvants

For vaccine preparation, OVA was dissolved in endotoxin-free water and mixed or emulsified with the different commercial adjuvants according to the manufacturer’s instructions. Briefly, LPS-EB Vaccigrade™ (LPS), Chitosan Vaccigrade™ (Chitosan), and Quil-A™ (InvivoGen) were mixed with the antigen at working concentrations of 25, 100, and 10 \(\mu\)g per mouse, respectively, in physiological solution. The other emulsion adjuvants were prepared by agitation (1400 rpm at RT) for at least 30 min. Inject™ Alum adjuvant (Alum, Thermo Scientific) was added to the antigen suspension at a final volume ratio of 1:1, and the same procedure was used to prepare the emulsion of the antigen with complete and incomplete Freund’s adjuvant (CFA/IFA, Sigma-Aldrich). AddaVax™ (InvivoGen) and Montanide™ ISA 51 and Montanide™ ISA 720 (Seppic) were emulsified at a 50/50 (v/v) ratio with the antigen dissolved in water.

Cell lines

The following murine lymphoma cell lines were used: EL-4 (thymoma, H-2\(^\text{d}\)) and EG7-OVA (EL-4 cells expressing OVA). Cells were maintained in complete medium and DMEM supplemented with 10% fetal bovine serum. EG7-OVA cells were always grown in the presence of the antibiotic gentamicin (0.4 mg/mL) (Invitrogen) for transgene selection.

Animals

Six- to 8-week-old female BALB/c, CD1, and C57BL/6 mice were purchased from Charles River Laboratories or bred at the IOV-IRCCS Specific Pathogen-Free animal facility. CB6F1 (Envigo) mice were housed at Statens Serum Institut (Copenhagen, Denmark). The experimental protocols were approved by the Italian Ministry of Health (Authorization No. 1249/2015-PR) or the European Community Directive (License No. 2014-15-2934-01065). All handling and procedures were performed in compliance with the European Community Directive 86/609 for the care and use of laboratory animals.

Immunization protocols and serum collection

Mice were immunized with antigen plus adjuvant in final volumes of 20 \(\mu\)L by intramuscular (i.m.) injection into the tibialis anterior (TA) muscle, 200 \(\mu\)L by intraperitoneal (i.p.) administration, and 100 \(\mu\)L by intravenous (i.v.) inoculation. Animals were vaccinated in accordance with different immunization schedules: either a single injection or a standard schedule, which consisted of a primary injection on day 0 and two boosters on days 14 and 21, was performed with different antigen concentrations. The corresponding sera were collected on day 0 as a baseline control, before every subsequent immunization, and every month.
thereafter for up to 1 year. Blood samples were collected from the mandibular vein of mice anesthetized with isoflurane/oxygen.

Evaluation of the humoral immune response
The antibody response to antigen in the serum of immunized mice was determined by enzyme-linked immunosorbent assay (ELISA). Briefly, twofold serial dilutions of mouse sera (from 1:50 to 1:3200) were added to antigen-precocated plates (Costar Assay Plate Half Area, Corning) and incubated for 1 h at RT prior to incubation with a HRP-conjugated secondary antibody (anti-mouse IgG, IgG1, IgG2a, or IgG2b, Biotechnologies) for 1 h at RT. To develop the reaction, plates were washed and incubated with OPD peroxidase substrate (Sigma-Aldrich), and the reaction was stopped with 3 N HCl. The optical density was read in a Victor X4 microplate reader (PerkinElmer) at 490 nm. The concentration of unknown samples was determined by interpolation in accordance with a properly generated standard curve.

Evaluation of cytotoxic immune response
Spleens from mice subjected to i.m. immunization with 10 µg OVA either unconjugated, conjugated with HA, mixed or emulsified with the other commercial adjuvants as described above, were harvested on day 30, and mixed lymphocyte tumor cell cultures (MLTCs) were established by in vitro stimulation of 25 × 10^6 splenocytes with 1 × 10^5 irradiated (60 Gy) OVA-expressing EG.7 tumor cells. Cell cultures were maintained in complete medium for 5 days. Supernatants were collected from MLTCs after 72 h of incubation and immediately tested with a mouse IFN-γ ELISA kit (R&D Systems) following the manufacturer’s instructions. The cytotoxic activity of MLTCs was assessed in a 4-h 51Cr-release assay performed after 5 days of culture. Briefly, EL-4 and EG.7-OVA cells were used as target cells; EL-4 cells were pulsed with 10 µm R&D Systems following the manufacturer’s instructions. Percent lysis was calculated as previously reported.

Biotolerability analysis
To compare toxicity induced by HA or other adjuvants at the injection site, BALB/c mice were subjected to one i.m. injection with 10 µg OVA257-264 HMC class I peptide (SIINFEKL, JPT Peptide Technologies GmbH) or nonspecific beta galactosidase_{36-103} peptide (DAPITYTV, Cribi Biotechnology Center, University of Padua, Italy). All target cells were labeled with 100 µCi 51Cr for 1 h at 37°C and plated with the effector cells. The supernatant was transferred to a scintillation plate (PerkinElmer) and measured using a Top Count gamma counter (PerkinElmer). Percent lysis was calculated as previously reported.

Hyaluronan is a natural and effective immunological adjuvant for... A Dalla Pietà et al.
maturation. DCs were harvested and analyzed by flow cytometry for their expression of maturation markers. Briefly, cells were stained at 4 °C for 20 min in the dark with PE-conjugated antibodies specific for mouse CD11c, CD40, CD80, and CD86 (Miltenyi Biotec S.r.l.), and FITC-conjugated anti-MHC Class II molecule antibodies (Becton Dickinson). Finally, cells were sorted with a FACSCalibur flow cytometer (Becton Dickinson) and analyzed as previously described.

Statistical analysis
All statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad Software). The results were analyzed for statistical significance by using multiple two-tailed Student's t tests or one-way analysis of variance (ANOVA) for comparisons among multiple groups, as specified in the figure legends. The data are reported as the means ± standard deviations (SDs) unless otherwise noted.

RESULTS
Synthesis and characterization of HA-antigen bioconjugates
HA was chemically modified by activating the desired percentage of its carboxyl groups and, in turn, introducing aldehyde groups. This synthesis approach produced short pendant chains of 4-aminobutyraldehyde diethyl acetal in the HA backbone that, after deprotection, provide the aldehyde groups for protein conjugation without degrading the HA backbone, as occurs during aldehyde formation by periodate oxidation of HA. This approach preserves the structure of the polymer and simplifies the characterization of the conjugates (Fig. 1a). HA-acetal with different MWS was prepared with the desired degrees of aldehyde modification ranging from 3 to 10 mol%. The exact degree of modification was calculated by 1H-NMR spectroscopy, as shown for HA200kDa-acetal (Fig. 1b). Before conjugation to antigens, HA-acetal derivatives were activated to HA-aldehyde by mild acid hydrolysis. The antigen OVA (as an example for any other antigen used in this work) was conjugated to different MW HA-aldehydes (HA 500–700 kDa, HA 200 kDa, HA 50 kDa, or HA 15 kDa), and the resulting bioconjugates were analyzed by SEC-HPLC (Fig. 1c). The peak of OVA appeared at 7.7 min, whereas the elution profile of the HA-conjugated OVA antigen showed a new peak at 6 min. After purification, the product was analyzed by SEC-HPLC to ensure the elimination of unreacted protein (Fig. 1d). The size of HA with different MWs and the resulting conjugates was determined by DLS (Supplementary Table 1). The antigen loading rate for HA-OVA ranged between 11 and 13% (w/w).

HA-conjugated antigens elicit strong and durable humoral immune responses
BALB/c mice were subjected to i.m. injection with 10 μg of different protein antigens: OVA, SOD, BSA, hGH, TT, H5N1, Vk3-20, and RABV G. Proteins were either unconjugated or conjugated to HA and were administered according to a standard immunization schedule consisting of a primary injection on day 0 followed by two boosters on days 14 and 21 (Fig. 2a). ELISA of sera collected on day 30 revealed that exogenous proteins conjugated to HA elicited strong antigen-specific antibody responses (Fig. 2b). Notably, this occurred in the absence of any added adjuvant, thus suggesting that HA does act per se as an adjuvant capable of promoting relevant humoral responses against different protein antigens. To thoroughly determine whether HA possesses adjuvant features, the endotoxin-free OVA model antigen was adopted for subsequent studies. Antigen-specific humoral
immune responses induced by the HA-OVA bioconjugate were evaluated in terms of quantity, quality, and persistence and compared to those induced by OVA admixed with alum, the gold standard adjuvant for human vaccines. The titers of OVA-specific total IgG and IgG1, IgG2a, and IgG2b subclasses were measured and monitored over time. The results obtained on day 30 after three rounds of immunization showed that the protein alone induced only negligible IgG production, which increased upon alum addition. Conversely, animals immunized with HA-OVA exhibited a very robust anti-OVA humoral response, with a high IgG titer in comparison to that in animals immunized with alum + OVA. Additionally, HA not only promoted the induction of higher IgG1 titers, a feature associated with a Th2-like immune response in mice, but also, unlike alum + OVA, was able to elicit the production of IgG2a and IgG2b subclasses, typical of a Th1-biased response (Fig. 2c). Therefore, HA produced a more balanced Th1/...
Th2 response against the target antigen in BALB/c mice, although the Th2 component remained dominant. IgG production in the sera of immunized mice was monitored for up to 1 year, and the results showed that the HA-induced humoral response was long lasting, peaking after the third antigen injection (day 30) and remaining detectable for the subsequent 12 months (Fig. 2d). Notably, IgG$_{2a}$ and IgG$_{2b}$ were also present 1 year after immunization with the HA-based bioconjugate. The persistence of circulating antibodies for a prolonged time has been reported to be associated with the detection of long-lived plasma cells (LLPCs) in the BM of vaccinated mice.28–31 Accordingly, immunization with HA-OVA progressively led to the establishment of a small but recognizable OVA-specific antibody-secreting population of LLPCs in the BM compartment (Supplementary Fig. 1).

Comparison of different injection routes revealed that HA-OVA induced high IgG titers even when injected via the i.p. and i.v. routes (Fig. 3a). In particular, this latter administration route stimulated a long-lasting humoral response based on all the IgG subclasses, as observed for i.m. injection (Fig. 3b). Importantly, HA-OVA effectively promoted relevant antibody production in infant and aged mice. In particular, the results in young mice even exceeded the results observed in adult mice, while aged mice showed wider variability, although ultimately, all were responsive (Supplementary Fig. 2). The adjuvanticity of HA was also confirmed in different mouse strains, all of which showed strong IgG production with the standard vaccination protocol (Fig. 3c). Taken together, these results indicate that HA is able to stimulate a strong and long-lasting antibody response against a wide array of different protein antigens, irrespective of the injection route, age, and genetic background of the host.

The adjuvanticity of HA relies on chemical conjugation to the antigen and molecular size of the polymer.

To evaluate the role played by chemical conjugation of HA to the antigen in the adjuvanticity of the polymer, humoral responses were assessed in mice receiving OVA simply mixed with HA (HA + OVA) and compared to those in mice receiving OVA alone or HA-OVA. Quantification of total IgG and related subclasses in the sera of BALB/c mice immunized according to the standard schedule showed that HA simply mixed with OVA completely lost its adjuvanticity. Thus, IgG production in mice immunized with HA + OVA was comparable to that in mice immunized with OVA alone, clearly indicating that the covalent binding of HA to the antigen is critically required for HA to exert its adjuvant effect (Fig. 3d). Since
the molecular size of HA fragments is responsible for their different functions and biological effects, we sought to determine whether it can also influence the adjuvanticity of HA. Therefore, HA fragments with different MWs (500, 50, and 15 kDa) were conjugated to OVA and compared to our standard HA-OVA bioconjugate (200 kDa HA). After the first antigen inoculation (day 14, Fig. 3e), only 200 kDa HA was able to induce an IgG response, which increased progressively upon subsequent administration. On the other hand, OVA conjugated to 50 kDa HA was much less efficient, as at least two antigen administrations were required to produce a detectable response, although the resulting IgG titers never approached those induced by the 200 kDa bioconjugate on day 30. Additionally, while the large-sized HA (500 kDa) induced only marginal production of IgG, 15 kDa HA was totally inefficient even after three doses. Overall, the adjuvanticity of HA relies on its chemical conjugation to the antigen and its molecular size. Thus, these results prompted us to use 200 kDa HA covalently linked to the antigen as a standard in all subsequent experiments.

HA-based immunization requires no antigenic boost and allows antigen dose sparing

To assess the efficacy of HA as an adjuvant, we performed additional immunization experiments by reducing either the number of administrations or the dose of injected antigen. Long-term follow-up of a single-shot immunization schedule revealed that HA-based vaccination was able to induce a long-lasting humoral response without requiring further booster immunizations (Fig. 4a). This result was completely different from that observed for alum, which was unable to elicit detectable antibody production after a single inoculation but required repeated immunization, as shown in Fig. 2c, d. Analysis of IgG subclasses on day 30 after vaccination revealed that the HA-induced humoral response was mainly due to IgG1, although a low amount of IgG2a was detected (Fig. 4b). Thereafter, mice were immunized with lower antigen concentrations according to the standard schedule (Fig. 4c). The results obtained with 0.1 µg of OVA revealed that HA succeeded in inducing detectable production of IgG even at this low antigen dose and required just two antigen injections to establish this response. In animals receiving 1 µg of OVA, the results almost completely mirrored those obtained with the higher dose employed. Conversely, alum was largely inefficient in inducing IgG production when 0.1 and 1 µg of OVA were used and required at least two injections of 10 µg of antigen to be effective. Thus, HA acts as an effective adjuvant that is capable of promoting strong humoral responses even without antigenic boosts and with very low concentrations of antigen, two of the most desirable features of an ideal adjuvant.

HA performs efficiently compared to other adjuvants

To compare the HA-induced humoral response with that induced by other adjuvants, different commercially available compounds were selected from the most common classes and tested in different mouse strains either according to the standard schedule or by a single injection. Analysis of antibody responses in BALB/c mice after a single priming dose revealed that HA-induced IgG production was only lower than those induced by CFA/IFA (not for human use) and, interestingly, superior to that induced by all the other adjuvants tested (Fig. 5a). After immunization according to the standard schedule, HA-induced IgG titers approached the levels induced by CFA/IFA and the two Montanide formulations but were still higher than the levels achieved with the other adjuvants tested (Fig. 5b). This higher performance was even more marked in C57BL/6 mice, where lower IgG production is generally observed (Fig. 5c). Indeed, HA-stimulated antibody titers were very close to those observed in CFA/IFA-treated mice and were higher than those achieved with the other adjuvants. Notably, the HA-induced total IgG and IgG subclass responses were comparable or even superior to responses elicited by adjuvants similar to those in clinical use (e.g., alum and AdvaVax) under all the tested conditions (Fig. 5 and Supplementary Fig. 3). A time course quantification of total IgG was carried out in BALB/c mice.
immunized according to the standard schedule and revealed that the HA-based IgG production pattern had a trend similar to that detected for the most efficient adjuvants tested (Fig. 5d).

Taken together, the results of these comparative experiments showed that the adjuvant effect of HA is at least comparable to that exerted by very active experimental adjuvants but largely exceeds that of adjuvant systems similar to those approved for human use (Alum and AddaVax).

Fig. 5 HA performs well compared to other adjuvants. Anti-OVA total IgG concentration in sera (1:100 dilution) collected on day 30 from BALB/c (a, b) and C57BL/6 (c) mice subjected to i.m. immunization with 10 μg OVA alone, conjugated to HA, or mixed with different adjuvants. Immunization schedules are shown above each graph and consisted of a single injection (a) or a standard schedule (b, c). The sample size is shown in each graph. d Quantification of the antigen-specific total IgG concentration at different time points after the first injection in BALB/c mice immunized as in (b) (n = 12 mice/group). e Splenocytes collected on day 30 from C57BL/6 mice vaccinated with 10 μg of OVA administered with different adjuvants (standard schedule) were restimulated in vitro with EG.7-OVA cells (MLTCs) and evaluated 5 days later for lytic activity against target cells. Cytotoxicity against different targets is expressed as LU10/10⁶ effector cells. f IFN-γ in supernatants of MLTCs set up as described above and tested after 72 h of activation. In (e, f), each symbol represents an individual mouse, and the bars indicate the means ± SDs. The data were analyzed using one-way ANOVA; comparisons between the OVA or HA-OVA group and other groups are shown (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; P > 0.05 if not indicated)
HA stimulates OVA-specific cytotoxic responses

The ability of HA-OVA to induce production of the IgG2a and IgG2b subclasses suggested that i.m. administration of HA also stimulates a Th1 immune response, thus implying an impact on cell-mediated immunity. To assess this aspect, splenocytes from C57BL/6 mice subjected to i.m. immunization with 10 µg of OVA alone or adjuvanted with HA, alum, LPS, chitosan, Quil-A, CFA/IFA, AddaVax, and Montanide ISA 51 or ISA 720 were stimulated with syngeneic EG.7-OVA tumor cells in MLTC. The potential of effector populations to specifically kill OVA-expressing target cells was then determined by ⁵¹Cr-release assays. The results showed induction of lytic activity against EL-4 cells pulsed with the OVA257-264 octapeptide SIINFEKL and against EG.7-OVA target cells by CFA/IFA, AddaVax, LPS, Montanide ISA 51, and Quil-A. Interestingly, immunization with HA also led to the generation of a cytotoxic response able to recognize and kill the target cells, albeit with a slightly lower efficiency than that of well-known Th1-skewing adjuvants (Fig. 5e). These data were supported by...
analysis of MLTC supernatants, which showed IFN-γ secretion by the HA-OVA, LPS, Quil-A, CFA/IFA, AddaVax, and Montanide groups (Fig. 5f), thus reinforcing the concept that HA is also able to elicit OVA-specific cytotoxic responses.

HA is fully biocompatible and does not induce inflammation at the injection site. To test the reactogenicity of HA and evaluate its potential induction of local toxicity in comparison to that of other commercial adjuvants, BALB/c mice were subjected to i.m. immunization with 10 µg OVA either alone or adjuvanted. The remarkable biotolerability of HA-based conjugates was already described by our laboratory and was confirmed by assessment of toxicity in mice vaccinated via the i.m. route. HA-injected animals indeed showed no signs of suffering, while the other adjuvants (mainly alum, CFA/IFA, Quil-A, and Montanide) induced macroscopic signs of inflammation, such as flushing and swelling of injected muscles even after the first injection. Thereafter, both muscle integrity and the presence of local inflammatory reactions were evaluated by histological analysis of TA muscles harvested at different time points. Hematoxylin and eosin staining of samples collected 24 h and 7 days after injection revealed that the HA-injected muscles had a totally preserved and intact tissue texture, with no detectable inflammatory cell infiltration (Supplementary Fig. 4). Histological observations in mice immunized with HA-OVA were indeed comparable with those in mice after administration of OVA alone or mixed with the other adjuvants.

Fig. 7  Time course analysis of OVA distribution in LNs from immunized mice. a Representative images of lymph nodes collected at different time points after i.m. injection of 10 µg of OVA alone, mixed with alum or conjugated to HA; sections were stained with the mHPC panel described in the “Materials and methods” section, and images were acquired at ×4 magnification with a Mauna Quantitative Pathology Workstation. Only OVA+ cells (yellow) and nuclei (DAPI, blue) are visualized. b Time course quantification of the intensity of OVA-associated fluorescence signals expressed as counts per lymph node (counts/LN). Cumulative data from three independent experiments are presented (n = 3 mice; 6 LNs/group). Multiple t-tests were performed (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; *P > 0.05 if not indicated).
of OVA alone, which also lacked signs of inflammatory reactions at the inoculation site. In contrast, muscles from mice injected with all the other commercial adjuvants displayed massive recruitment of inflammatory cells even at 24 h after immunization, which persisted 7 days later. In addition, traces of local damage likely caused by the accumulation of oil particles were detected in specimens from mice immunized with water-in-oil emulsion adjuvants such as CFA/IFA and Montanide. The absence of local inflammatory reactions at the inoculation site was confirmed by analysis of the total cell number in muscles after vaccine injection, showing that alum + OVA induced massive cellular recruitment that increased over time (Supplementary Fig. 5a). In contrast, the number of cells in muscles harvested from HA-immunized mice was comparable to that in naïve or OVA-injected muscles.

Additionally, analysis of supernatants obtained from muscle tissue digest showed that all the injected groups displayed similar levels of inflammatory cytokines early after injection (6 h) (Supplementary Fig. 5b). However, very high cytokine levels persisted in supernatants from alum-injected muscles and remained detectable after 48 h. This pattern clearly differed from that in muscles injected with OVA and HA-OVA, which generally displayed constant or decreased quantities of cytokines during the observation period. In general, the levels of cytokines detected in muscles from mice immunized with HA-OVA were comparable to those found in mice receiving OVA alone and in untreated mice, confirming the absence of a noticeable inflammatory reaction at the inoculation site and generally indicating that HA is extremely biocompatible and well tolerated when injected via the i.m. route.

HA induces antigen accumulation in lymph nodes draining the injection site

Data obtained from biotolerability analysis suggested that HA could act differently from classical immunological adjuvants, which trigger strong inflammatory responses. Thus, in vivo biodistribution studies aimed at monitoring fluorophore-conjugated OVA were carried out to assess the biological fate of HA-linked antigens. In vivo optical imaging indicated that OVA conjugated to HA is partially retained in muscle, unlike alum, which allows the antigen to persist at the inoculation site (Fig. 6a). On the other hand, OVA injected alone or simply mixed with HA appeared to be rapidly cleared from the injection site even after 4 h, likely as a consequence of protein degradation and dye elimination through the kidneys and urine, as indicated by the increased fluorescence signals measured in the liver and
Hyaluronan is a natural and effective immunological adjuvant for... A Dalla Pietà et al.

bladder (Fig. 6a and Supplementary Fig. 6). Interestingly, mice injected with HA-OVA showed a clearly detectable fluorescence signal that promptly localized at the inguinal LNs. This signal was significantly higher than that measured in all the other groups at both early and late time points (4, 8, and 72 h), suggesting that HA promotes antigen accumulation in draining LNs (Fig. 6b). The rapid drainage and preferential accumulation of fluorescent HA-conjugated OVA in LNs following i.m. injection was confirmed by both flow cytometry and fluorescence microscopy of draining inguinal LNs harvested 4 h postinjection (Fig. 6c, d). Flow cytometric analysis of dissociated LNs revealed an increased percentage of OVA-positive cells in the LNs of mice injected with the HA bioconjugate compared to OVA- and alum-injected mice (Fig. 6c). The presence of the antigen in LNs was macroscopically detectable as a bluish accumulation only in specimens from HA-injected mice. Moreover, only specimens derived from HA-injected mice, not LNs from OVA- and alum-injected mice, showed cell-associated fluorescence signals in the tissue (Fig. 6d). In an attempt to finely determine the spatial distribution of OVA and the nature of cells involved in the interaction with the antigen, FFPE sections of LNs harvested at different time points after vaccination were subjected to mIHC. Time course analysis of antigen-associated fluorescence signal intensity mirrored the results of in vivo biodistribution studies and showed a higher fluorescence intensity in the HA-OVA specimens at early time points (4 and 8 h) than in the alum and OVA specimens (Fig. 7a, b). Moreover, the density of OVA^+ cells detected in LNs of HA-OVA-injected mice at 4 h postinjection was higher than those in LNs of alum- and OVA-injected mice (Fig. 8a, b). A detailed colocalization analysis revealed that LNs of mice receiving HA-OVA displayed significantly increased numbers of OVA^+ lymphatic endothelial cells (LYVE-1^+) and DCs (CD11c); however, no significant differences in terms of macrophages were detected within the three groups (Fig. 8a, c). Collectively, these results strongly support a role for the LYVE-1 receptor and lymphatic drainage in sustaining the accumulation of HA-bound OVA in LNs where, in turn, it is captured more efficiently by DCs.

Conjugated HA acts as a DAMP to stimulate DCs

Considerable evidence in the literature indicates that 4–8-mer HA derivatives act as DAMPs, stimulating APCs through interaction with specific TLRs. Such fragments are physiologically generated by HAase, which is widely expressed in different tissues and has a central role in HA catabolism. To assess whether small HA fragments can also be generated from bioconjugates through the action of HAase and hence can potentially act as DAMPS, HA-OVA was incubated in vitro with HAase. First, an HPLC-based standard curve of different-sized HA derivatives was used to calculate the MW of fragments originating from unconjugated 200 kDa HA digested with HAase (Supplementary Fig. 7a). The results of this quantitative analysis revealed that HAase digested the HA moiety and generated derivatives with MWs ranging from 0.5 to 129 kDa. Thereafter, the same digestion protocol was applied to HA-OVA. Although quantitative analysis could not be conducted because of the presence of the protein, the results clearly demonstrated that HAase led to the generation of different and small products from HA-OVA (Supplementary Fig. 7b). Then, to assess whether the HA-OVA derivatives liberated from digestion of the bioconjugate are endowed with immunostimulatory properties, BMDC cultures were stimulated in vitro with a commercial 4-mer HA derivative (SH4) or HAase-treated HA or HA-OVA bioconjugate (Supplementary Fig. 8a, b). As previously reported, SH4 increased the expression of BMDC surface maturation markers to levels similar to those resulting from treatment with the positive control LPS. Notably, both HAase-digested HA and HA-OVA were similarly efficient in stimulating BMDC maturation. Interestingly, undigested HA and HA-OVA also induced increases in marker expression, albeit to a slightly lower extent than those observed in the other groups, likely due to endogenous cell-associated HAase activity. Collectively, these data indicate that HA-OVA mirrors the ability of HA to act as a DAMP for DCs, ultimately leading to their activation/maturation.

DISCUSSION

Vaccination is one of the greatest medical achievements to date. Attempts over the years to improve the quality and purity of vaccines for increased safety and reduced adverse events have led to the development of subunit vaccines composed of purified, synthetic, and recombinant antigens with paradoxically limited immunogenicity. Consequently, modern subunit vaccines require the addition of adjuvants to improve their effectiveness by enhancing and modulating the immunogenicity of antigens and facilitating their delivery and presentation to the immune system. Recently, due to the emergence of anti-vaccination movements, a growing sense of alarmism has increased the negative public opinion about vaccines; in particular, adjuvants have been held responsible for the major side effects of vaccine formulations. Therefore, safety issues have become one of the major challenges, and the urgent need for more biocompatible adjuvants is emerging as a main topic in vaccine research.

Although the potential use of HA as an adjuvant was suggested by Kim et al. in the context of transdermal vaccination, here, we clearly establish that HA does actually act as an adjuvant per se upon chemical conjugation to the antigen, without the addition of other compounds or external stimulation. This use distinctly differs from previous applications, where HA was essentially exploited as a mere carrier selected for its excellent physicochemical and targeting properties for different vaccine formulations (i.e., nanoparticles and liposomes). Specifically, our results showed that the simple binding of HA to the antigen in the absence of other adjuvants is capable of inducing robust and long-lasting antigen-specific humoral responses characterized by the production of not only the IgG1, but also the IgG2a and IgG2b subclasses. The potential of HA as an immune stimulator was also highlighted by its capability to reduce the requirements for further boosting and to be effective even with extremely low amounts of antigen. By allowing improved immunogenicity and response modulation accompanied by both dose and antigen sparing, HA-based vaccines can be expected to positively impact patient compliance and to reduce vaccination costs, thus fulfilling the main requirements for an ideal adjuvant.

We compared HA not only with the gold standard alum but also with other commercial adjuvants, such as Quil-A, AddaVax, CFA/IFA, chitosan, LPS, and two types of Montanide. This comparison was conducted in a large-scale study using the same model antigen, antigen doses, immunization regimens, and mouse models. Collectively, our data indicate that HA-OVA induces a level of IgG production that is comparable to or greater than that induced by all the other tested compounds, particularly adjuvants similar to those in clinical use (e.g., alum and AddaVax). Indeed, only the CFA/IFA-induced humoral responses were stronger than that induced by HA-OVA; however, these adjuvants are not applicable for human use because of excessive toxicity. Although we showed that HA-OVA stimulates the production of IgG2a, this was reflected only by slight induction of cell-mediated immune responses, thus indicating that the Th2 response in this model is certainly dominant. However, the type of immunity elicited could also depend on the type of antigen, and hence, we cannot exclude the possibility that the cytotoxic response induced by HA could differ if it were conjugated to other antigens, such as viral or tumor proteins. On the other hand, even though elicitation of cell-based responses is desirable for the development of vaccines against intracellular pathogens or tumors, long-term therapeutic benefits against viral diseases mainly require the induction of...
neutralizing antibodies and long-lived responses. In this regard, HA efficiently induced the production of persistent antibodies, which correlated with the generation of antigen-specific Ab-secreting LLCPs in BM. Notably, high Ab titers were detected in different mouse strains and in both infant and aged mice, suggesting that HA-based vaccines might be particularly advantageous for poorly responding subjects such as aged persons and children.

Furthermore, HA presents some additional remarkable features that make it appealing as an adjuvant. The polymer confers water solubility on the conjugated protein and can be chemically linked to a wide array of protein antigens, thus assuring unique versatility in its use. In this regard, chemical modification and conjugation are frequently adopted to enhance the functionality of TLR agonists, and this approach was clearly confirmed by our data, which demonstrated a critical requirement for chemical conjugation of HA to the antigen to exert its adjuvant effect. Moreover, HA is highly biocompatible, being a natural polymer physiologically present in the human body, and therefore appears well suited to fulfill all major toxicological requirements for an adjuvant. Although classical immunological adjuvants act by triggering inflammatory responses at the site of injection, excessive local reactivity may also constitute a major limitation. HA appears to act differently, since HA-based conjugates proved to be both efficient and very well tolerated and did not induce any apparent signs of local or systemic toxicity. Notably, this high biotolerability provides a unique opportunity for immunization through non-muscular administration routes. Indeed, HA-OVA was also highly immunogenic and well tolerated when administered intravenously or intraperitoneally, suggesting that HA could be delivered via immunization routes that are considered more efficient in inducing Th1 responses or those that are confirmed to establish local immunity, such as intramuscular administration. This latter aspect is particularly promising, especially if we take into account the physical properties of HA and its ability to interact with mucosal membranes.

The intrinsic functional properties and the lack of inflammatory signs at the injection site raise immediate questions about the mechanism of action of HA. In this regard, in vivo biodistribution studies supported by fluorescence microscopy, flow cytometry, and miHc indicated that HA promotes rapid translocation of the antigen to draining LNs, thus promoting its accumulation at a site where encounters with ACPs are facilitated. This enhanced delivery to LNs likely relies on the LYVE-1 receptors present on the endothelin of lymphatic vessels, which promote drainage of the bioconjugate through the lymphatic system. Thus, by following the same biological fate of the physiological polymer, HA-based conjugates enhance the bioavailability of the antigen in LNs and favor its encounter with DCs. In addition, we speculate that HA may undergo degradation, leading to the generation of immunostimulatory fragments that activate DCs and stimulate antigen recognition and presentation to effector cells. In fact, HA-OVA, like HA alone, is digested by HAase in vitro, and the derived LMW fragments induce DC maturation, indicating that products of HA-OVA digestion mirror the ability of HA to act as DAMPs for DCs. Hence, HA functions as both a delivery system and an immune stimulator, overcoming the limitation of other adjuvants that work only as carriers or immune potentiators.

Although further studies are required to finely elucidate the mechanism of action of this polymer, this work advances the promising use of HA as a vaccine adjuvant that combines the unique immunomodulatory features of a TLR agonist with the tolerability properties of a fully natural polymer. Moreover, since HA is easy to produce and has already been exploited in several different medical applications, and its conjugation chemistry is well known, our vaccination approach has the potential for rapid and scalable clinical translation.

ACKNOWLEDGEMENTS
This work was supported by Fondazione AIRC under IG 2018—ID. 21354 project—P.I. Rosato Antonio, S per Mille 2019—ID. 22759 program—G.L. Rosato Antonio, BIGID219MON2 from S per Mille 2018, and Veneto Institute of Oncology IOV-IRCCS to I.M.M., Bando Ricerca Covid 2019 from Fondazione Cassa di Risparmio di Padova e Rovigo. P.D.B. wishes to thank the Italian Ministry of Health, which partially contributed to the achievements of the study through RC ISVES 08/06. The authors would like to thank Prof. R. Dolcetti (Centro di Riferimento Oncologico di Aviano, CRO-IRCCS, Aviano, Italy) for providing the Vx5-20 antigen.

AUTHOR CONTRIBUTIONS
A.D.P., D.C., I.M.M., and A.R. designed the experiments and wrote the paper; A.D.P., D.C., and I.M.M. performed the experiments and interpreted the data; A.G. carried out chemical conjugation and bioconjugate synthesis; A.T. conducted miHc analysis; S.D.S. contributed to the analysis and interpretation of flow cytometry data; L.M.-A. performed digestion experiments and HPLC analyses; V.B. collected blood samples from mice; G.K.P. and D.C. contributed to the analysis of inflammatory cytokines at the injection site; P.D.B. produced the rabies virus G glycoprotein; G.P. supervised the chemical part of the project; I.M.M. and A.R. conceived and directed the project; and all authors read and approved the final paper.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41423-021-00667-y.

Competing interests: A.D.P., D.C., I.M.M., and A.R. are inventors on Patent Application No. PCT/IB2019/059122 submitted on October 24, 2019 related to “Hyaluronic acid as a natural adjuvant for protein and peptide-based vaccines.” All other authors declare that they have no competing interests.

REFERENCES
1. Fallacara, A., Baldini, E., Manfredini, S. & Vertuani, S. Hyaluronic acid in the third millennium. Polymers 10, 701 (2018).
2. Kim, H. et al. Hyaluronate and its derivatives for customized biomedical applications. Biomaterials 123, 155–171 (2017).
3. Montagner, I. M. et al. A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer. J. Control. Release 236, 79–89 (2016).
4. Montagner, I. M. et al. Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. PLoS ONE 9, e112240 (2014).
5. Banzato, A. et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 14, 3598–3606 (2008).
6. Stern, R., Asari, A. & Sugahara, K. Hyaluronan fragments: an information-rich system. Eur. J. Cell Biol. 85, 699–715 (2006).
7. Liang, J., Jiang, D. & Noble, P. W. Hyaluronan as a therapeutic target in human diseases. Adv. Drug Deliv. Rev. 97, 186–203 (2016).
8. Weigel, J. A. & Weigel, P. H. Characterization of the recombinant rat 175-kDa hyaluronan receptor for endocytosis (HARE). J. Biol. Chem. 278, 42802–42811 (2003).
9. Naor, D. Editorial: interaction between hyaluronic acid and its receptors (CD44, RHAMM) regulates the activity of inflammation and cancer. Front. Immunol. 7, 10–13 (2016).
10. Baneri, S. et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144, 789–801 (1999).
11. Lee-Sayer, S. S. M. et al. The where, when, how, and why of hyaluronan binding by immune cells. Front. Immunol. 6, 1–12 (2015).
12. Mumert, M. E. Immunologic roles of hyaluronan. Immunol. Res. 31, 189–206 (2005).
13. Chandran, S. S., Verhoeven, D., Teijaro, J. R., Fenton, M. J. & Farber, D. L. TLR2 engagement on dendritic cells promotes high frequency effector and memory CD4 T cell responses. J. Immunol. 183, 7832–7841 (2009).
14. Adams, S. Toll-like receptor agonists in cancer therapy. Immunotherapy 71, 3831–3840 (2009).
15. Mumert, M. E. et al. Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in antigen presentation. J. Immunol. 169, 4322–4331 (2002).
16. Kim, K. S. et al. Noninvasive transdermal vaccination using hyaluronan nanoparticle and laser adjuvant. Adv. Funct. Mater. 26, 2512–2522 (2016).
17. Lahiri, A., Das, P. & Chakravortty, D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 26, 6777–6783 (2008).
18. Duthie, M. S., Windish, H. P., Fox, C. B. & Reed, S. G. Use of defined TLR ligands as adjuvants within human vaccines. *Immunol. Rev.* **239**, 178–196 (2011).
19. Wen, Y. & Shi, Y. Alum: an old dog with new tricks. *Emerg. Microbes Infect.* **5**, 1–5 (2016).
20. Garçon, N., Segal, L., Tavares, F. & Van Mechelen, M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. *Vaccine* **29**, 4453–4459 (2011).
21. Penny, M. A. et al. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. *Lancet* **387**, 367–375 (2016).
22. Shinchi, H. et al. Enhancement of the immunostimulatory activity of a TLR7 ligand by conjugation to polysaccharides. *Bioconjug. Chem.* **26**, 1713–1723 (2015).
23. Gao, D. et al. Toll-like receptor 7 inactive ligands enhanced cytokine induction by conjugation to weak antigens. *ChemMedChem* **10**, 977–980 (2015).
24. Ignacio, B. J., Albin, T. J., Esser-Kahn, A. P. & Verdoess, M. Toll-like receptor agonist conjugation: a chemical perspective. *Bioconjug. Chem.* **29**, 587–603 (2018).
25. Mero, A., Pasqualin, M., Campisi, M., Renier, D. & Pasut, G. Conjugation of hyaluronan to proteins. *Carbohydr. Polym.* **92**, 2163–2170 (2013).
26. Meslin, F. X., Kaplan, M. M. & Koprowski, H. in Laboratory Techniques in Rabies (World Health Organization, 1996).
27. Tosi, A. et al. Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. *Oncoimmunology* **6**, e1313371 (2017).
28. Slifka, M. K., Matloubian, M. & Ahmed, R. Bone marrow is a major site of long-term antibody production after acute viral infection. *J. Virol.* **69**, 1895–1902 (1995).
29. Manz, R. A., Thiel, A. & Radbruch, A. Lifetime of plasma cells in the bone marrow. *Nature* **388**, 133–134 (1997).
30. Pracht, K. et al. A new staining protocol for detection of murine antibody-secreting plasma cell subsets by flow cytometry. *Eur. J. Immunol.* **47**, 1389–1392 (2017).
31. Lemke, A. et al. Long-lived plasma cells are generated in mucosal immune responses and contribute to the bone marrow plasma cell pool in mice. *Mucosal Immunol.* **9**, 83–97 (2016).
32. Zeng, M., Nourishirazi, E., Guinet, E. & Nouri-Shirazi, M. The genetic background influences the cellular and humoral immune responses to vaccines. *Clin. Exp. Immunol.* **186**, 190–204 (2016).
33. Termeer, C. C. et al. Oligosaccharides of hyaluronan are potent activators of dendritic cells. *J. Immunol.* **165**, 1863–1870 (2000).
34. Termeer, C. et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. *J. Exp. Med.* **195**, 99–111 (2002).
35. O’Hagan, D. T., Friedland, L. R., Hanon, E. & Didierlaurent, A. M. Towards an evidence based approach for the development of adjuvanted vaccines. *Curr. Opin. Immunol.* **47**, 93–102 (2017).
36. Del Giudice, G., Rappooli, R. & Didierlaurent, A. M. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. *Semin. Immunol.* **39**, 14–21 (2018).
37. Skwarczynski, M. et al. Poly(aminoo acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines. *Sci. Adv.* **6**, eaax2285 (2020).
38. Lee, Y. -H. et al. A polymeric conjugate foreignizing tumor cells for targeted immunotherapy in vivo. *J. Control. Release* **199**, 98–105 (2015).
39. Moon, S., Shin, E. C., Noh, Y. W. & Lim, Y. T. Evaluation of hyaluronic acid-based combination adjuvant containing monophosphoryl lipid A and aluminum salt for hepatitis B vaccine. *Vaccine* **33**, 4762–4769 (2015).
40. Leone, M. et al. Hyaluronan-based dissolving microneedles with high antigen content for intradermal vaccination: formulation, physicochemical characterization and immunogenicity assessment. *Eur. J. Pharm. Biopharm.* **134**, 49–59 (2019).
41. Reed, S. G., Berthelet, S., Coler, R. N. & Friede, M. New horizons in adjuvants for vaccine development. *Trends Immunol.* **30**, 23–32 (2009).
42. Amanna, I. J. & Sifika, M. K. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. *Virology* **411**, 206–215 (2011).
43. Lynn, G. M. et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. *Nat. Biotechnol.* **33**, 1201–1210 (2015).
44. Zhang, L., Wang, W. & Wang, S. Effect of vaccine administration modality on immunogenicity and efficacy. *Expert Rev. Vaccines* **14**, 1509–1523 (2015).
45. Vasvani, S., Kulkarni, P. & Rawlani, D. Hyaluronic acid: a review on its biology, aspects of drug delivery, route of administrations and a special emphasis on its approved marketed products and recent clinical studies. *Int. J. Biol. Macromol.* https://doi.org/10.1016/j.ijbiomac.2019.11.066 (2019).
46. Yoo, E. et al. Hyaluronic acid conjugates of TLR7/8 agonists for targeted delivery to secondary lymphoid tissue. *Bioconjug. Chem.* **29**, 2741–2754 (2018).
47. Hubbell, J. A., Thomas, S. N. & Swartz, M. A. Materials engineering for immunomodulation. *Nature* **462**, 449–460 (2009).
48. Scheibner, K. A. et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. *J. Immunol.* **177**, 1272–1281 (2014).
49. Muto, J. et al. Hyaluronic acid digestion controls DC migration from the skin. *J. Clin. Investig.* **124**, 1309–1319 (2014).
50. Christensen, D. Vaccine adjuvants: why and how. *Hum. Vaccin. Immunother.* **12**, 2709–2711 (2016).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021